Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Patients will be recruited among patient refered to our department for a breast cancer and needing an axillary dissection. Enrolled patients will have an injection of Lanreotide or placebo the day before surgery when they arrive in their room. The quantity of lymph in axillary drain will by daily noted until day 4. The patient will be evaluated at D15, D30 and M6 for pain, lymphocele and adverse events.

Data will be compared in the 2 groups.

Inclusion Criteria:

• Adult patient (> 18 years),
• Patient undergoing an axillary lymphadenectomy for breast cancer
• Patient giving her agreement after being informed

Exclusion Criteria:

• Patients that don't understand the trial
• Type 2 diabetic patients
• Cyclosporine treatment
• Biliary lithiasis
• Pregnancy or breast feeding
• Allergic reaction to Lanréotide or same class treatments
• Patient included in another trial within the last 30 days